邢唷��>� FH��E��欹�[€ 餜��$bjbj88螑螑� ��44}}}}}��8�$�,�Bl////ccc��$��PB�}ccccc�}}//4��cZ}/}/��c��/��0蔑$\/��0B��K��}��cc�ccccc��cccBcccc��ccccccccc4C: Dear Friends and Colleagues, We extend a warm welcome to the leading scientists, doctors, industrialists and young researchers to BIT Life Sciences� 1st Annual World Congress of Immunodiseases and Therapy 2010 (WCIT-2010) with the theme of 揃oosting Health and Vitality�, which will take place in Beijing, China on May 15-17, 2010. With your great contributions in the study and research on immunology, you are expected to take part in this international and HYPERLINK "javascript:void(0)" compositive conference. The program track info at the bottom of the e-mail is for your reference. WCIT is a focused conference to present and deliberate the advances in immunology, which is significant, timely and important to the health of humanity. The well selected topics cover across disciplinary breaking, from concept to therapy. It is anticipated over 500 global specialists to get together to present and share their cutting-edge technologies and up-to-date researches in an innovative and invigorating combination of presentations, symposia, discussions, panel discussion sessions and associated young scientist poster sessions along with exhibition of technology and new products. The comprehensive and intellectually stimulating scientific program of the first annual will embrace a broad spectrum of topics in basic science, medical research, diagnosis, prevention, clinical treatment and therapy of immune diseases. We believe that WCIT-2010 will definitely provide you an ideal platform for promoting ground breaking research and seeding potential collaborations for relevant parties of tailored interests not only in R & D areas but also the industrial and medical sectors. The Initiative of WCIT-2010 will include both oral and poster presentations from academic and industrial settings. We hope to set a stage for all the medical doctors, the academicals, the clinical and the industrial researchers to make your research and innovations known with equal opportunity, means to join this event actively. The capital city, Beijing has long been the political, cultural, scientific and diplomatic center of China. It is both a tribute to China's proud history and a gateway to China's future. Beijing Olympics brought the world a great surprise for the Olympics opening ceremony, WCIT-2010 will be held in Beijing International Convention Center (BICC) which located very near to The National Olympic Sports Center, it's a great advantage to see this amazing place. Also, May is the most pleasant season in spring, you are encourage to have lecture tour to other cities in China. We look forward to seeing you in Beijing for a stimulating and enjoyable conference! Below is the program track info.Kayla Liu Program Coordinator The Organizing Committee of WCIT-2010 Tentative Program Symposium 1: Research Frontiers on Immune Diseases Session 1-1: The Immunity Diseases Molecular Mechanisms Session 1-2: Immunopathology, Etiology and Pathogenic Role of Complement Session 1-3: Genetics of Immune and Autoimmunity Diseases Session 1-4: Cell and Molecular Biology of Autoimmunity Session 1-5: Tumor Immunology Session 1-6: Innate to Acquired (Adaptive) Immunity and Diseases Session 1-7: Toll-like Receptors and Pattern Recognition Receptors Session 1-8: Immune Signal Transduction and Cross-talk Session 1-9: Immune Regulations- Regulatory T Cells and T Cell Subsets Session 1-10: Dendritic Cells, Macrophages and other Innate Immune Cells Session 1-11: Human Immunology and Immunodeficiencies Session 1-12: Hypersensitivity, Antigen Processing and Presentation Session 1-13: Immunological Inflammations and Vascular Injury Session 1-14: Neuroimmunology, Neuroendocrine Immunology and Psychoneuroimmunology Session 1-15: Natural Killer Cells, Apoptosis & Immunity Session 1-16: Infection and Immunity, Epidemiology of Immune Diseases Session 1-17: Prophylaxis and Intervention Session 1-18: Mucosal Immunology Session 1-19: Immunochemistry & Immunobiology Session 1-20: Immune燭olerance in Autoimmune Disease Symposium 2: Leading Technologies in Immunology Session 2-1: System Biology and Computational Immunology Session 2-2: Hybridoma Technology Session 2-3: Sensitivity and Accuracy in Imaging Immunity Session 2-4: Immunogenomics & Immunoproteomics Session 2-5: Biochips, Microarray Based Technology Session 2-6: New Immune營ntervention Technologies Session 2-7: Small RNAs in Development and Immune Diseases Session 2-8: Nucleic Acids in Innate Immunity Session 2-9: The Stem Cells and Implications in Immune Diseases Session 2-10: The SCID Mouse as Model of Immune Diseases Symposium 3: Immune Disease Drug Discovery & Development Session 3-1: Molecular Targets and Biomarkers of Immunotherapeutics Session 3-2: Computer Aided Drug Design & Medicinal Chemistry Session 3-3: Immunopharmacology Session 3-4: Immunosuppression and Immunotherapy Development Session 3-5:燙ytokines, Chemokine and Cell Adhesion Molecules and Drug Discovery Session 3-6: Gene燼nd燙ell燭herapy Session 3-7: Monoclonal燗ntibody燼nd Antibody Engineering Session 3-8: Innate Immunity and Novel Vaccines Session 3-9: Novel Drug Delivery Systems of Immunotherapeutics Session 3-10: Traditional Medicines for Immune and Inflammatory Diseases Symposium 4: Medical Research and Immune Diseases Session 4-1: Immunity and Emerging Infectious Disease Session 4-2: Hormones燼nd營mmune燫esponse Mediated Diseases Session 4-3: Allergy, Asthma & Clinical Immunology Session 4-4: Autoimmunity Mediated Diseases Session 4-5: Lymphocyte Development and Functions in Immune Diseases Session 4-6: Immunosenescence and Clinical Applications Session 4-7: Immunity and Aging Session 4-8: Reproductive Immunology Session 4-9: Neonatal and Maternal Immunization Session 4-10: Translational Immunology Symposium 5: Diagnostics & Immunotherapy of Major Diseases Session 5-1: Biomarkers for Molecular Diagnostics of Immune Diseases Session 5-2: Insulin-Dependent Diabetes Mellitus Session 5-3: Allergy, Asthma and Rheumatoid Arthritis Session 5-4: Inflammatory Bowel Disease and Ocular Inflammation Session 5-5: Vasculitis and Cardiovascular Diseases Session 5-6: Lung Inflammation and Fibrosis Session 5-7: Autoimmune Hepatitis and Chronic Liver Diseases Session 5-8: Multiple Sclerosis, Scleroderma, Myasthenia Gravis, and Neuromuscular Diseases Session 5-9: Systemic Lupus Erythematosus and and Other Connective Tissue Diseases Session 5-10: Psoriasis, Allergic Skin Diseases and Immunodermatology Session 5-11: Immunotherapy on Reemerging TB and Malaria Session 5-12: Immunological Renal Diseases, and Organ Transplant Rejection Session 5-13: Major Cancers- Breast Cancer Session 5-14: Major Cancers-Head, Brain and Neck Cancers Session 5-15: Major Cancers- Cervical and Ovarian Cancer Session 5-16: Major Cancers- Pancreatic , Prostate, and Renal Cancer Session 5-17: Major Cancers- Leukemia, Lymphoma & Melanoma Session 5-18: Major Cancers- Lung Cancer Session 5-19: Major Infectious Diseases- HIV/AIDS and Other Viral Infections Session 5-20: Major Infectious Diseases-Resistant Bacterial Infections Symposium 6: Benchmark Analysis and Case Studies Session 6-1: Anticancer Drugs Session 6-2: Anti-inflammatory Drugs Session 6-3: Anti-allergy and Asthma Drugs Session 6-4: Anti-Infectious Drugs Session 6-5: Anti-Autoimmune Drugs [i�� M R m � � � � � � 镘锸锕铷杽铷q躛O^B^h!>hv60JB*ph�h!>hv60JOJQJ^J%jh!>hv60JOJQJU^J$h!>h�6�CJKHOJQJ^JaJ#h!>h�6�6丆JOJQJ^JaJ#h!>hv66丆JOJQJ^JaJ h!>h�6�CJOJQJ^JaJ h!>h_$CJOJQJ^JaJ#h!>hv6CJH*OJQJ^JaJ$h!>hv6CJKHOJQJ^JaJ h!>hv6CJOJQJ^JaJR ��"��'_��:|��>��$a$gd!>$a$gd!>d�1$[$\$gd!>gd!>d�1$[$\$gdm^�gdm^�gdv6� Q R Z � � � � � ?TY��%6Ny�� $%2:>rv��碥啥啥啥啥啥啥啥啥啥啥啥啥啥啥啥啥啥啥啥６惗啥}啥$h!>h黙�CJKHOJQJ^JaJ$h!>h翶3CJKHOJQJ^JaJ$h!>h�6CJKHOJQJ^JaJ$h!>h�6�CJKHOJQJ^JaJ$h!>hv6CJKHOJQJ^JaJ!h!>0JCJOJQJ^JaJo($h!>hv60JCJOJQJ^JaJ1��->MNR`d{��%0�!wxy��'��:�碲碲碲碲碲碲碲碲碲碲砩股ι噓dudud h!>丑!>颁闯翱闯蚕闯镑闯补闯#丑!>丑!>5丆闯翱闯蚕闯镑闯补闯丑!>丑!>颁闯(翱闯蚕闯镑闯丑!>丑!>5丱闯蚕闯镑闯补闯$丑!>丑!>颁闯碍贬翱闯蚕闯镑闯补闯丑!>颁闯碍贬翱闯蚕闯镑闯补闯!丑!>颁闯碍贬翱闯蚕闯镑闯补闯辞($丑!>丑尘镑�颁闯碍贬翱闯蚕闯镑闯补闯$丑!>丑惫6颁闯碍贬翱闯蚕闯镑闯补闯#>��?��<]��*L��U�� $Ifgdp`�$a$gd!>gd!>�:~��l��8��gd!>$a$gd!>`kd$$If�0蟒��F�B t��6��2� x2�2�3�4�B�a�ytp`��#�#�$�$�$�$�$�$�$�$�$�$�$�$逶略吃略略煕煕煕煕�hp`�jhp`�Uh!>h!> he€o(h!>CJOJQJ^JaJo(#h!>h!>5丆JOJQJ^JaJ h!>h!>CJOJQJ^JaJ4h!>h!>B*CJOJQJ\乛JaJmH phsH �&Z��#Hy��!S��* h � !]!�!�!"E"~"�"�"��$a$gd!>gd!>�"'#u#�#�#�#$3$^$�$�$�$�$�$�$�$�$�$�$�$�$�$�$��gdv6$a$gd!>gd!>61�82P:pe€皞. 捌A!�"�#悹$悹%�癝班惄�$$If栻�!vh5��5�#v�#v:V t��6�5��5�2� x2�2�3�4� B�ytp`�j��666666666vvvvvvvvv666666>666666666666666666666666666�6666666666�66666666666hH66666666666666666666666666666666666666666666666666666666666666666�62�� 0@P`p€��2(�� 0@P`p€�� 0@P`p€�� 0@P`p€�� 0@P`p€�� 0@P`p€�� 0@P`p€�8X�V~ OJPJQJ_HmH nHsH tHR`�Rv6ck噀$1$a$(CJKHOJQJ_HaJmH nHsH tH$A`��$ 貫祂=刉[SOBi@��B0nf恏�*CJOJQJS*€Y(^JaJo(phF堳"﨩�A"v6trans.�R. v60yb鑜Fh噀,gCJaJD��aDv60 yb鑜Fh噀,g CharCJOJPJQJ^JaJPK!倞��[Content_Types].xml瑧薺�0E鲄䞍卸豶�(ヘ微Iw},�浔-j弰4 蛇w旄P�-t#b螜{U畯銧擉T閁^h卍}悒)蛔*1P�' 揯鬃W孱0)櫐T闉9<搇�#ぼ$yi}佸;纞@囨�(顚跄H滖男u�*D谞z內/0娗盃瘥�$€�X3aZ⒁锣,癉0j~�3叨蝏沩~i>�赝3縗`�?�/�[�G殁\�!�-跼k.搒粣..椃碼婵�?��PK!ブх�6_rels/.rels剰蟡�0囷吔冄}Q颐%v/C/�(h"�脎O� �劋秣�=孂釘� 毆免C?薶醰=�偵叅�%[xp啠{鄣_糚眩<�1�0�堎O糝瓸d焉襃E�4b$q_�槥�6L吁R�7`畯ㄉ�趁0虨O��,錏n7擫i鋌〃/鉙綈╡械根铸��PK!ky��theme/theme/themeManager.xml蘉 � @醹愘7c�(Eb菜�C�A菭覠圩邈�7芜諞K Y,� 奺�.埛饇,�ㄚH�,l崆骈x纱�逫萻Q}#諓叚递值+�!�,較�$j=婫W栌�)釫�+& 8��PK!�m�Qtheme/theme/theme1.xml靁MoE�#�F{oc'vGu�h覨盵糟x=逎zvg53N�j廐H垈z�饴昛 $石I)*E阓酀欇鮊�&IA�!裎>秣羌3緓镹男>掤搁鲍蟇L0斈屵呖z�迃rx鳔脅�稔h9T�8奣/魁煜��?�鍃Y�雒'蟸�3S琦棌~蜩鶅O_|w��)馉镉圚t��=乤�+d NG�1-Rl苼�1諶J鴚T锠疢1Kｃ柩"�o he浪撣幝絇L-憒%��绗臙�甴Y7�'qP.\L姼=岟薲穛炷�3I爋fi��墸�.帽�墘B�Rb�-J款P_p蒅茛▍i㎏鷗郿訉h汧梚櫷o�7;7Q嫵2染媱珼�>a�/銐翾�>嶺厌W� 藬霱卂膗H剄�)薶�胺�+:Vi豾�4r態裶汐橌"r嫃�!帓2l徠a麃C奲此U|嚮!8^顩�8�>�軤仯�,A魶壭眲V韙鄨�讕厏ls囔�14犁_=,涩返o聻TV 跥陲"苎︑鎎H唼灮�'�.�4熯x薜躻-戏蹺鮸褾;氕衯踯`嘼3"G'�e\昮H柊O话ㄩ恬愪'�$劘i_wp伬� �>�*靺8�魂i&丩Y%\铝�,楎謝視=瞩伭�壵阱綔�r6f� 提3储淭厥厰)橗:陋Z�K�誏玸ゅ&C鏜兣軟0€ [浪玴@注醏�j扣�7媺耏咹唜H�i荤cT5A蕆跑@顢腍驇馴AZC硙i' RQ\m伕,zo�,僩Q襲{�Y\,Nψ�/�=溷ら嵿L_��.跆嘫7C�6韽-fS宄h62密"5咍麥罭H凾[X�65太4X�%Y龡豚殖2纅鷎h辈绅痠~tCKF#猥b�+趙�1m鑵�4`眹!�:U翞!昿5a:倊€{4韒笫m蝘�o�萎c杽8m泛D矹秔S枪姗�豓1铘�?#S奿�?3E�'pS�2�疳W`る甸q]( ┻08樲�w别� n撏A鲺[s枃)k8皓= Aa?R� d趻删c楿咏瞬d)#換ueb�恾满�捷C!ず�&i0福>�4魫S�7鋥�z虮�F箎�4�sKvUKo瘸椒h垀1砵YU€奥V蠬塔5U8錠k;譁潘鮈9堚寂皹D 荀 ��?*|FL� 迪鳡�"A3兇伂>驳�类诲尘2颈痴值殍そ杕謌<殒r�8[kv抶熞蠃p鎶sj�,潩z伛礭[鑚堨�叆Qv𐓭縤u鈨��-高�0%M2羙J描�3u舘%覎��PK! 褠煻'theme/theme/_rels/themeManager.xml.rels剰M �0匃倃oo雍�&輬协�勪5 6?$Q祉 �,.嘺緳i粭澤c2�1h�:闀q毩m胳嶡RN壻;d癭値o7�g慘(M&$R(.1榬'J摐袏T鶂�8V�"＆A然蠬鱱}狇�|�$絙{�朠�除8塯/]As賲(⑵锑#洩L蔥汉倪��PK-!倞��[Content_Types].xmlPK-!ブх�6+_rels/.relsPK-!ky��theme/theme/themeManager.xmlPK-!�m�Q�theme/theme/theme1.xmlPK-! 褠煻'� theme/theme/_rels/themeManager.xml.relsPK]� �8�� $>��"�$��X��餈� @��€€€�餒 ��0�( � �饞��0�( � �養 �S�� ?�� l{L U � � M\^l|�}�7@��k}��3<%7��K\�� 1 5 ��3333y � � � � � ��2� �:霢 W!>_$ .翶3v6�6凮:0j;€sI� RjtRFdS哣[ b(h�/nFWnLG{豀{�~.e€酭��5��p`�0a�.m�m^��*�;O�+q�匥��Y�a9��黙�漌�� ; �謟��vC��6�岰��@€� � 燨� � ��@��Unknown��G��*郃x� �Times New Roman5�€Symbol3.��*郈x� �Arial7.��爗 @�Calibri;��(媅SOSimSunA��犽 B�Cambria Math 1��hX肇fh:�& F`�4F`4!?!%),.:;>?]}�� & 0 2 3 : !6"000 00 0000006�:�>兀﨑㖞㘎⺗�� =�@�\�]�^��$([{�� 0 0000000Y㘚⺌��;�[��個��2僸HX �$P��v62!xx��Annietoshiba�鄥燆鵒h珣+'迟0T�� (4<DL�AnnieNormaltoshiba10Microsoft Office Word@怤Z@卣xP&�@X�\/�F`�胀諟.摋+,D胀諟.摋+,�� X`lt|��4�� 8@_PID_HLINKS�A`l`javascript:void(0)} �� !"#$��&'()*+,-./01234��6789:;<��>?@ABCD��G��Root Entry�� Fp谗$\/�I€Data ��1Table��%�WordDocument��88SummaryInformation(��5DocumentSummaryInformation8��=CompObj��u�� F#Microsoft Office Word 97-2003 文档 MSWordDocWord.Document.8�9瞦